Research and Markets: Global Dengue Vaccines Opportunity Analysis and Forecasts 2014-2020

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/f57w6z/opportunityanalyze) has announced the addition of the "Opportunity Analyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020" report to their offering.

After the Launch of the First Dengue Vaccine in 2015, the Market is Projected to Experience Rapid Growth Through 2020

In 2015, it is projected that the dengue vaccine market to be valued at $69.6m across the five pharmaceutical markets covered in this report: Brazil, India, Mexico, Singapore, and Thailand. Two of the earliest adopters of dengue vaccines, Brazil and Mexico, are together expected to account for well over 95% of the 2015 market share, with sales of $44.6m (64.1% market share) and $23.6m (34.0% market share), respectively. For the purposes of this report, GlobalData defines the market as the sales of dengue vaccines in the countries of interest that are likely to incorporate these vaccines into their routine immunization programs.

By 2020, it is expected that dengue vaccine sales to grow substantially and reach a combined $398.6m in Brazil, India, Mexico, Singapore, and Thailand, at a Compound Annual Growth Rate (CAGR) of 41.8%. This rapid uptake of dengue vaccines will be driven primarily by the inclusion of live-attenuated vaccines in national immunization programs. Brazil ($97.0m; 24.4% market share) and Mexico ($216.7m; 54.4% market share) are anticipated to continue their dominance of the market, although GlobalData projects India ($58.6m; 14.7% market share), Singapore ($16.1m; 4.0% market share), and Thailand ($10.0m; 2.5% market share) to still experience solid growth from 2015-2020. Sales growth, however, will likely be hindered by the arrival of less expensive, publically-supplied vaccines in Brazil and India, which are expected to rapidly garner patient share from premium-priced vaccines.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Current Surveillance, Prevention, and Control Measures

6 Unmet Needs Assessment and Opportunity Analysis

7 Research and Development Strategies

8 Pipeline Assessment

9 Pipeline Valuation Analysis

10 Appendix

For more information visit http://www.researchandmarkets.com/research/f57w6z/opportunityanalyze

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious Diseases

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious Diseases